DDIT3 and diffuse large B-cell lymphoma: In conclusion, we showed that the Ro+R-CHOP combination is safe in treatment-naïve DLBCL patients, that the addition of roflumilast inhibited VEGF-A secretion in the urine and PI3K activity in the PBMCs, and that this new therapeutic scheme may be particularly active in specific genetic subsets of DLBCL.